Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 13, 2014, Pages 5509-5524

  Plano, Daniel ^a,b   Amin, Shantu ^a   Sharma, Arun K ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; F 12509A; NATURAL PRODUCT; PHOSPHOTRANSFERASE INHIBITOR; PHYTOSPHINGOSINE; SESQUITERPENE DERIVATIVE; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 1 INHIBITOR; SPHINGOSINE KINASE 2; SPHINGOSINE KINASE 2 INHIBITOR; SPHINGOSINE KINASE 3 INHIBITOR; SPHINGOSINE KINASE 4 INHIBITOR; SPHINGOSINE KINASE 5 INHIBITOR; SPHINGOSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTHMA; CANCER GROWTH; CANCER THERAPY; CARDIOVASCULAR DISEASE; CATALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME SUBSTRATE; FIBROSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; RHEUMATOID ARTHRITIS;

CLOFIBRATE; DRUG COMBINATIONS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; LYSOPHOSPHOLIPIDS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PRACTOLOL; SPHINGOSINE;

EID: 84904323486     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4011687     Document Type: Article

References (144)

1. Signorelli, P.; Ghidoni, R. Breast cancer and sphingolipid signalling J. Dairy Res. 2005, 72, 5-13 (Pubitemid 41323090)
2. Huwiler, A.; Zangemeister-Wittke, U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy Crit. Rev. Oncol. Hematol. 2007, 63, 150-159 (Pubitemid 46990918)
3. Taha, T. A.; Hannun, Y. A.; Obeid, L. M. Sphingosine kinase: biochemical and cellular regulation and role in disease J. Biochem. Mol. Biol. 2006, 39, 113-131
4. Cuvillier, O. Sphingosine kinase-1-a potential therapeutic target in cancer Anti-Cancer Drugs 2007, 18, 105-110 (Pubitemid 44967421)
5. Xia, P.; Gamble, J. R.; Wang, L.; Pitson, S. M.; Moretti, P. A.; Wattenberg, B. W.; D'Andrea, R. J.; Vadas, M. A. An oncogenic role of sphingosine kinase Curr. Biol. 2000, 10, 1527-1530 (Pubitemid 32003646)
6. Alshaker, H.; Sauer, L.; Monteil, D.; Ottaviani, S.; Srivats, S.; Bohler, T.; Pchejetski, D. Therapeutic potential of targeting SK1 in human cancers Adv. Cancer Res. 2013, 117, 143-200
7. Heffernan-Stroud, L. A.; Obeid, L. M. Sphingosine kinase 1 in cancer Adv. Cancer Res. 2013, 117, 201-235
8. Li, W.; Yu, C. P.; Xia, J. T.; Zhang, L.; Weng, G. X.; Zheng, H. Q.; Kong, Q. L.; Hu, L. J.; Zeng, M. S.; Zeng, Y. X.; Li, M.; Li, J.; Song, L. B. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients Clin. Cancer Res. 2009, 15, 1393-1399
9. Liu, G.; Zheng, H.; Zhang, Z.; Wu, Z.; Xiong, H.; Li, J.; Song, L. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy BMC Cancer 2010, 10, 495
10. Li, J.; Guan, H. Y.; Gong, L. Y.; Song, L. B.; Zhang, N.; Wu, J.; Yuan, J.; Zheng, Y. J.; Huang, Z. S.; Li, M. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival Clin. Cancer Res. 2008, 14, 6996-7003
11. Guan, H.; Song, L.; Cai, J.; Huang, Y.; Wu, J.; Yuan, J.; Li, J.; Li, M. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells PLoS One 2011, 6, e19946
12. Kapitonov, D.; Allegood, J. C.; Mitchell, C.; Hait, N. C.; Almenara, J. A.; Adams, J. K.; Zipkin, R. E.; Dent, P.; Kordula, T.; Milstien, S.; Spiegel, S. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts Cancer Res. 2009, 69, 6915-6923
13. Rosa, R.; Marciano, R.; Malapelle, U.; Formisano, L.; Nappi, L.; D'Amato, C.; D'Amato, V.; Damiano, V.; Marfe, G.; Del Vecchio, S.; Zannetti, A.; Greco, A.; De Stefano, A.; Carlomagno, C.; Veneziani, B. M.; Troncone, G.; De Placido, S.; Bianco, R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models Clin. Cancer Res. 2013, 19, 138-147
14. Cuvillier, O.; Ader, I.; Bouquerel, P.; Brizuela, L.; Gstalder, C.; Malavaud, B. Hypoxia, therapeutic resistance, and sphingosine 1-phosphate Adv. Cancer Res. 2013, 117, 117-141
15. Pchejetski, D.; Doumerc, N.; Golzio, M.; Naymark, M.; Teissie, J.; Kohama, T.; Waxman, J.; Malavaud, B.; Cuvillier, O. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models Mol. Cancer Ther. 2008, 7, 1836-1845
16. Liu, Z.; Macritchie, N.; Pyne, S.; Pyne, N. J.; Bittman, R. Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors and activators Bioorg. Med. Chem. 2013, 21, 2503-2510
17. Baek, D. J.; MacRitchie, N.; Pyne, N. J.; Pyne, S.; Bittman, R. Synthesis of selective inhibitors of sphingosine kinase 1 Chem. Commun. 2013, 49, 2136-2138
18. Mei, T.-W.; Luo, Y.; Feng, X.-J.; Lu, W.; Yang, B. Suzuki coupling based synthesis and in vitro cytotoxic evaluation of fingolimod and analogues Tetrahedron 2013, 69, 2927-2932
19. French, K. J.; Schrecengost, R. S.; Lee, B. D.; Zhuang, Y.; Smith, S. N.; Eberly, J. L.; Yun, J. K.; Smith, C. D. Discovery and evaluation of inhibitors of human sphingosine kinase Cancer Res. 2003, 63, 5962-5969 (Pubitemid 37187498)
20. Wang, Z.; Min, X.; Xiao, S. H.; Johnstone, S.; Romanow, W.; Meininger, D.; Xu, H.; Liu, J.; Dai, J.; An, S.; Thibault, S.; Walker, N. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis Structure 2013, 21, 798-809
21. Selvam, S. P.; Ogretmen, B. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance Handb. Exp. Pharmacol. 2013, 216, 3-27
22. Hannun, Y. A.; Obeid, L. M. Principles of bioactive lipid signalling: lessons from sphingolipids Nat. Rev. Mol. Cell Biol. 2008, 9, 139-150 (Pubitemid 351158911)
23. Morad, S. A.; Cabot, M. C. Ceramide-orchestrated signalling in cancer cells Nat. Rev. Cancer 2013, 13, 51-65
24. Orr Gandy, K. A.; Obeid, L. M. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors Biochim. Biophys. Acta 2013, 1, 157-166
25. Chalfant, C. E.; Spiegel, S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling J. Cell Sci. 2005, 118, 4605-4612 (Pubitemid 41646371)
26. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P. G.; Coso, O. A.; Gutkind, S.; Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate Nature 1996, 381, 800-803 (Pubitemid 26243122)
27. Ponnusamy, S.; Meyers-Needham, M.; Senkal, C. E.; Saddoughi, S. A.; Sentelle, D.; Selvam, S. P.; Salas, A.; Ogretmen, B. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance Future Oncol. 2010, 6, 1603-1624
28. Johnson, K. R.; Johnson, K. Y.; Crellin, H. G.; Ogretmen, B.; Boylan, A. M.; Harley, R. A.; Obeid, L. M. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue J. Histochem. Cytochem. 2005, 53, 1159-1166 (Pubitemid 41262984)
29. Kharel, Y.; Mathews, T. P.; Gellett, A. M.; Tomsig, J. L.; Kennedy, P. C.; Moyer, M. L.; Macdonald, T. L.; Lynch, K. R. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate Biochem. J. 2011, 440, 345-353
30. Schnute, M. E.; McReynolds, M. D.; Kasten, T.; Yates, M.; Jerome, G.; Rains, J. W.; Hall, T.; Chrencik, J.; Kraus, M.; Cronin, C. N.; Saabye, M.; Highkin, M. K.; Broadus, R.; Ogawa, S.; Cukyne, K.; Zawadzke, L. E.; Peterkin, V.; Iyanar, K.; Scholten, J. A.; Wendling, J.; Fujiwara, H.; Nemirovskiy, O.; Wittwer, A. J.; Nagiec, M. M. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1 Biochem. J. 2012, 444, 79-88
31. Buehrer, B. M.; Bell, R. M. Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways J. Biol. Chem. 1992, 267, 3154-3159
32. Hamada, M.; Sumi, T.; Iwai, S.; Nakazawa, M.; Yura, Y. Induction of endonuclease G-mediated apopotosis in human oral squamous cell carcinoma cells by protein kinase C inhibitor safingol Apoptosis 2006, 11, 47-56 (Pubitemid 43151643)
33. Coward, J.; Ambrosini, G.; Musi, E.; Truman, J. P.; Haimovitz-Friedman, A.; Allegood, J. C.; Wang, E.; Merrill, A. H., Jr.; Schwartz, G. K. Safingol (l -threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway Autophagy 2009, 5, 184-193
34. Ling, L. U.; Tan, K. B.; Lin, H.; Chiu, G. N. The role of reactive oxygen species and autophagy in safingol-induced cell death Cell Death Dis. 2011, 2, e129
35. Schwartz, G. K.; Ward, D.; Saltz, L.; Casper, E. S.; Spiess, T.; Mullen, E.; Woodworth, J.; Venuti, R.; Zervos, P.; Storniolo, A. M.; Kelsen, D. P. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin Clin. Cancer Res. 1997, 3, 537-543 (Pubitemid 27211830)
36. Ling, L. U.; Lin, H.; Tan, K. B.; Chiu, G. N. The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells Int. J. Oncol. 2009, 35, 1463-1471
37. Kedderis, L. B.; Bozigian, H. P.; Kleeman, J. M.; Hall, R. L.; Palmer, T. E.; Harrison, S. D., Jr.; Susick, R. L., Jr. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents Fundam. Appl. Toxicol. 1995, 25, 201-217
38. Schwartz, G. K.; Haimovitz-Friedman, A.; Dhupar, S. K.; Ehleiter, D.; Maslak, P.; Lai, L.; Loganzo, F., Jr.; Kelsen, D. P.; Fuks, Z.; Albino, A. P. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells J. Natl. Cancer Inst. 1995, 87, 1394-1399
39. Dickson, M. A.; Carvajal, R. D.; Merrill, A. H., Jr.; Gonen, M.; Cane, L. M.; Schwartz, G. K. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors Clin. Cancer Res. 2011, 17, 2484-2492
40. Sachs, C. W.; Safa, A. R.; Harrison, S. D.; Fine, R. L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C J. Biol. Chem. 1995, 270, 26639-26648
41. Tan, K. B.; Ling, L. U.; Bunte, R. M.; Chng, W. J.; Chiu, G. N. In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia J. Controlled Release 2012, 160, 290-298
42. Sweeney, E. A.; Sakakura, C.; Shirahama, T.; Masamune, A.; Ohta, H.; Hakomori, S.; Igarashi, Y. Sphingosine and its methylated derivative N, N -dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines Int. J. Cancer 1996, 66, 358-366 (Pubitemid 26166198)
43. Shirahama, T.; Sweeney, E. A.; Sakakura, C.; Singhal, A. K.; Nishiyama, K.; Akiyama, S.; Hakomori, S.; Igarashi, Y. In vitro and in vivo induction of apoptosis by sphingosine and N, N -dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells Clin. Cancer Res. 1997, 3, 257-264 (Pubitemid 27107303)
44. Wang, H.; Maurer, B. J.; Liu, Y. Y.; Wang, E.; Allegood, J. C.; Kelly, S.; Symolon, H.; Liu, Y.; Merrill, A. H., Jr.; Gouaze-Andersson, V.; Yu, J. Y.; Giuliano, A. E.; Cabot, M. C. N -(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing Mol. Cancer Ther. 2008, 7, 2967-2976
45. Ghosh, S. C.; Auzenne, E.; Farquhar, D.; Klostergaard, J. N, N -Dimethylsphingosine-coumarin: synthesis, chemical characterization, and biological evaluation Bioconjugate Chem. 2007, 18, 731-735 (Pubitemid 47010792)
46. De Jonghe, S.; Van Overmeire, I.; Poulton, S.; Hendrix, C.; Busson, R.; Van Calenbergh, S.; De Keukeleire, D.; Spiegel, S.; Herdewijn, P. Structure-activity relationship of short-chain sphingoid bases as inhibitors of sphingosine kinase Bioorg. Med. Chem. Lett. 1999, 9, 3175-3180 (Pubitemid 29515403)
47. Johnson, C. R.; Chun, J.; Bittman, R.; Jarvis, W. D. Intrinsic cytotoxicity and chemomodulatory actions of novel phenethylisothiocyanate sphingoid base derivatives in HL-60 human promyelocytic leukemia cells J. Pharmacol. Exp. Ther. 2004, 309, 452-461 (Pubitemid 38542594)
48. Sharma, A. K. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247) Expert Opin. Ther. Pat. 2011, 21, 807-812
49. Paugh, S. W.; Paugh, B. S.; Rahmani, M.; Kapitonov, D.; Almenara, J. A.; Kordula, T.; Milstien, S.; Adams, J. K.; Zipkin, R. E.; Grant, S.; Spiegel, S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia Blood 2008, 112, 1382-1391
50. Chun, J.; Hartung, H. P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin. Neuropharmacol. 2010, 33, 91-101
51. Brinkmann, V.; Davis, M. D.; Heise, C. E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C. A.; Zollinger, M.; Lynch, K. R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors J. Biol. Chem. 2002, 277, 21453-21457 (Pubitemid 34952287)
52. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G. J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W.; Rosen, H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 2002, 296, 346-349 (Pubitemid 34303689)
53. Azuma, H.; Takahara, S.; Ichimaru, N.; Wang, J. D.; Itoh, Y.; Otsuki, Y.; Morimoto, J.; Fukui, R.; Hoshiga, M.; Ishihara, T.; Nonomura, N.; Suzuki, S.; Okuyama, A.; Katsuoka, Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models Cancer Res. 2002, 62, 1410-1419 (Pubitemid 34407800)
54. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment J. Urol. 2003, 169, 2372-2377 (Pubitemid 36576803)
55. Tanaka, T.; Takahara, S.; Hatori, M.; Suzuki, K.; Wang, J.; Ichimaru, N.; Suzuki, S.; Morozumi, K.; Okuyama, A.; Yamanaka, H. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine Cancer Lett. 2002, 181, 165-171 (Pubitemid 34518300)
56. Ubai, T.; Azuma, H.; Kotake, Y.; Inamoto, T.; Takahara, K.; Ito, Y.; Kiyama, S.; Sakamoto, T.; Horie, S.; Muto, S.; Takahara, S.; Otsuki, Y.; Katsuoka, Y. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft Anticancer Res. 2007, 27, 75-88 (Pubitemid 46363319)
57. Zheng, T.; Meng, X.; Wang, J.; Chen, X.; Yin, D.; Liang, Y.; Song, X.; Pan, S.; Jiang, H.; Liu, L. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice J. Cell. Biochem. 2010, 111, 218-228
58. Takabe, K.; Paugh, S. W.; Milstien, S.; Spiegel, S. "Inside- out" signaling of sphingosine-1-phosphate: therapeutic targets Pharmacol. Rev. 2008, 60, 181-195 (Pubitemid 351962008)
59. Kunkel, G. T.; Maceyka, M.; Milstien, S.; Spiegel, S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond Nat. Rev. Drug Discovery 2013, 12, 688-702
60. Zhang, L.; Wang, H. D.; Ji, X. J.; Cong, Z. X.; Zhu, J. H.; Zhou, Y. FTY720 for cancer therapy (review) Oncol. Rep. 2013, 30, 2571-2578
61. Sharma, S.; Mathur, A. G.; Pradhan, S.; Singh, D. B.; Gupta, S. Fingolimod (FTY720): first approved oral therapy for multiple sclerosis J. Pharmacol. Pharmacother. 2011, 2, 49-51
62. Parrill, A. L.; Wang, D.; Bautista, D. L.; Van Brocklyn, J. R.; Lorincz, Z.; Fischer, D. J.; Baker, D. L.; Liliom, K.; Spiegel, S.; Tigyi, G. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate J. Biol. Chem. 2000, 275, 39379-39384 (Pubitemid 32058961)
63. Deng, Q.; Clemas, J. A.; Chrebet, G.; Fischer, P.; Hale, J. J.; Li, Z.; Mills, S. G.; Bergstrom, J.; Mandala, S.; Mosley, R.; Parent, S. A. Identification of Leu276 of the S1P1 receptor and Phe263 of the S1P3 receptor in interaction with receptor specific agonists by molecular modeling, site-directed mutagenesis, and affinity studies Mol. Pharmacol. 2007, 71, 724-735 (Pubitemid 46294083)
64. Lim, K. G.; Tonelli, F.; Li, Z.; Lu, X.; Bittman, R.; Pyne, S.; Pyne, N. J. FTY720 analogues as sphingosine kinase 1 inhibitors J. Biol. Chem. 2011, 286, 18633-18640
65. Lim, K. G.; Tonelli, F.; Berdyshev, E.; Gorshkova, I.; Leclercq, T.; Pitson, S. M.; Bittman, R.; Pyne, S.; Pyne, N. J. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b Int. J. Biochem. Cell Biol. 2012, 44, 1457-1464
66. Pyne, S.; Pyne, N. J. New perspectives on the role of sphingosine 1-phosphate in cancer Handb. Exp. Pharmacol. 2013, 216, 55-71
67. Pyne, N. J.; Tonelli, F.; Lim, K. G.; Long, J. S.; Edwards, J.; Pyne, S. Sphingosine 1-phosphate signalling in cancer Biochem. Soc. Trans. 2012, 40, 94-100
68. Kim, J. W.; Kim, Y. W.; Inagaki, Y.; Hwang, Y. A.; Mitsutake, S.; Ryu, Y. W.; Lee, W. K.; Ha, H. J.; Park, C. S.; Igarashi, Y. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases Bioorg. Med. Chem. 2005, 13, 3475-3485 (Pubitemid 40545803)
69. Hara-Yokoyama, M.; Terasawa, K.; Kihara, A.; Kim, J. W.; Park, C. S.; Hirabayashi, Y.; Igarashi, Y.; Yanagishita, M. Sphingosine kinase 2 inhibitor accelerates Fas-mediated cell death progression in A2O/2J cells Open Bioact. Compd. J. 2008, 1, 22-27
70. Hara-Yokoyama, M.; Terasawa, K.; Ichinose, S.; Watanabe, A.; Podyma-Inoue, K. A.; Akiyoshi, K.; Igarashi, Y.; Yanagishita, M. Sphingosine kinase 2 inhibitor SG-12 induces apoptosis via phosphorylation by sphingosine kinase 2 Bioorg. Med. Chem. Lett. 2013, 23, 2220-2224
71. Nishi, T.; Miyazaki, S.; Takemoto, T.; Suzuki, K.; Iio, Y.; Nakajima, K.; Ohnuki, T.; Kawase, Y.; Nara, F.; Inaba, S.; Izumi, T.; Yuita, H.; Oshima, K.; Doi, H.; Inoue, R.; Tomisato, W.; Kagari, T.; Shimozato, T. Discovery of CS-0777: a potent, selective, and orally active S1P1 agonist ACS Med. Chem. Lett. 2011, 2, 368-372
72. Moberly, J. B.; Ford, D. M.; Zahir, H.; Chen, S.; Mochizuki, T.; Truitt, K. E.; Vollmer, T. L. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients J. Neuroimmunol. 2012, 246, 100-107
73. Humpf, H. U.; Schmelz, E. M.; Meredith, F. I.; Vesper, H.; Vales, T. R.; Wang, E.; Menaldino, D. S.; Liotta, D. C.; Merrill, A. H., Jr. Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N -palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor J. Biol. Chem. 1998, 273, 19060-19064 (Pubitemid 28366299)
74. Symolon, H.; Bushnev, A.; Peng, Q.; Ramaraju, H.; Mays, S. G.; Allegood, J. C.; Pruett, S. T.; Sullards, M. C.; Dillehay, D. L.; Liotta, D. C.; Merrill, A. H., Jr. Enigmol: a novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer Mol. Cancer Ther. 2011, 10, 648-657
75. Garnier-Amblard, E. C.; Mays, S. G.; Arrendale, R. F.; Baillie, M. T.; Bushnev, A. S.; Culver, D. G.; Evers, T. J.; Holt, J. J.; Howard, R. B.; Liebeskind, L. S.; Menaldino, D. S.; Natchus, M. G.; Petros, J. A.; Ramaraju, H.; Reddy, G. P.; Liotta, D. C. Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer ACS Med. Chem. Lett. 2011, 2, 438-443
76. Mays, S. G.; Baillie, M. T.; Miller, E. J.; Bushnev, A. S.; Pruett, S. T.; Culver, D. G.; Evers, T. J.; Gao, J.; Reddy, G. P.; Natchus, M. G.; Arrendale, R. F.; Howard, R. B.; Liotta, D. C.; Petros, J. A. 330 Fluorination of enigmol improves tissue uptake and effects in vivo prostate cancer efficacy J. Urol. 2013, 189, e133-e134
77. Foss, F. W., Jr.; Snyder, A. H.; Davis, M. D.; Rouse, M.; Okusa, M. D.; Lynch, K. R.; Macdonald, T. L. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists Bioorg. Med. Chem. 2007, 15, 663-677 (Pubitemid 44880732)
78. Foss, F. W., Jr.; Mathews, T. P.; Kharel, Y.; Kennedy, P. C.; Snyder, A. H.; Davis, M. D.; Lynch, K. R.; Macdonald, T. L. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs Bioorg. Med. Chem. 2009, 17, 6123-6136
79. Mathews, T. P.; Kennedy, A. J.; Kharel, Y.; Kennedy, P. C.; Nicoara, O.; Sunkara, M.; Morris, A. J.; Wamhoff, B. R.; Lynch, K. R.; Macdonald, T. L. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors J. Med. Chem. 2010, 53, 2766-2778
80. Kennedy, A. J.; Mathews, T. P.; Kharel, Y.; Field, S. D.; Moyer, M. L.; East, J. E.; Houck, J. D.; Lynch, K. R.; Macdonald, T. L. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells J. Med. Chem. 2011, 54, 3524-3548
81. Kharel, Y.; Raje, M.; Gao, M.; Gellett, A. M.; Tomsig, J. L.; Lynch, K. R.; Santos, W. L. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate Biochem. J. 2012, 447, 149-157
82. Liu, K.; Guo, T. L.; Hait, N. C.; Allegood, J.; Parikh, H. I.; Xu, W.; Kellogg, G. E.; Grant, S.; Spiegel, S.; Zhang, S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent PLoS One 2013, 8, e56471
83. French, K. J.; Upson, J. J.; Keller, S. N.; Zhuang, Y.; Yun, J. K.; Smith, C. D. Antitumor activity of sphingosine kinase inhibitors J. Pharmacol. Exp. Ther. 2006, 318, 596-603 (Pubitemid 44061234)
84. Leroux, M. E.; Auzenne, E.; Evans, R.; Hail, N.; Spohn, W.; Ghosh, S. C.; Farquhar, D.; McDonnell, T.; Klostergaard, J. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells Prostate 2007, 67, 1699-1717 (Pubitemid 350036956)
85. Bektas, M.; Johnson, S. P.; Poe, W. E.; Bigner, D. D.; Friedman, H. S. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells Cancer Chemother. Pharmacol. 2009, 64, 1053-1058
86. Loveridge, C.; Tonelli, F.; Leclercq, T.; Lim, K. G.; Long, J. S.; Berdyshev, E.; Tate, R. J.; Natarajan, V.; Pitson, S. M.; Pyne, N. J.; Pyne, S. The sphingosine kinase 1 inhibitor 2-(p -hydroxyanilino)-4-(p -chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells J. Biol. Chem. 2010, 285, 38841-38852
87. Ren, S.; Xin, C.; Pfeilschifter, J.; Huwiler, A. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p -hydroxyanilino)-4-(p -chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation Cell. Physiol. Biochem. 2010, 26, 97-104
88. Antoon, J. W.; Meacham, W. D.; Bratton, M. R.; Slaughter, E. M.; Rhodes, L. V.; Ashe, H. B.; Wiese, T. E.; Burow, M. E.; Beckman, B. S. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer J. Mol. Endocrinol. 2011, 46, 205-216
89. Sharma, A. K.; Sk, U. H.; Gimbor, M. A.; Hengst, J. A.; Wang, X.; Yun, J.; Amin, S. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs Eur. J. Med. Chem. 2010, 45, 4149-4156
90. Hengst, J. A.; Wang, X.; Sk, U. H.; Sharma, A. K.; Amin, S.; Yun, J. K. Development of a sphingosine kinase 1 specific small-molecule inhibitor Bioorg. Med. Chem. Lett. 2010, 20, 7498-7502
91. French, K. J.; Zhuang, Y.; Maines, L. W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J. J.; Green, C. L.; Keller, S. N.; Smith, C. D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2 J. Pharmacol. Exp. Ther. 2010, 333, 129-139
92. Beljanski, V.; Knaak, C.; Smith, C. D. A novel sphingosine kinase inhibitor induces autophagy in tumor cells J. Pharmacol. Exp. Ther. 2010, 333, 454-464
93. Antoon, J. W.; White, M. D.; Meacham, W. D.; Slaughter, E. M.; Muir, S. E.; Elliott, S.; Rhodes, L. V.; Ashe, H. B.; Wiese, T. E.; Smith, C. D.; Burow, M. E.; Beckman, B. S. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640 Endocrinology 2010, 151, 5124-5135
94. Antoon, J. W.; White, M. D.; Slaughter, E. M.; Driver, J. L.; Khalili, H. S.; Elliott, S.; Smith, C. D.; Burow, M. E.; Beckman, B. S. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 Cancer Biol. Ther. 2011, 11, 678-689
95. Beljanski, V.; Knaak, C.; Zhuang, Y.; Smith, C. D. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib Invest. New Drugs 2011, 29, 1132-1142
96. Gao, P.; Peterson, Y. K.; Smith, R. A.; Smith, C. D. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases PLoS One 2012, 7, e44543
97. Pennington, L. D.; Sham, K. K. C.; Pickrell, A. J.; Harrington, P. E.; Frohn, M. J.; Lanman, B. A.; Reed, A. B.; Croghan, M. D.; Lee, M. R.; Xu, H.; McElvain, M.; Xu, Y.; Zhang, X.; Fiorino, M.; Horner, M.; Morrison, H. G.; Arnett, H. A.; Fotsch, C.; Wong, M.; Cee, V. J. 4-Methoxy- N -[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: a potent and selective agonist of S1P1 ACS Med. Chem. Lett. 2011, 2, 752-757
98. Kurata, H.; Kusumi, K.; Otsuki, K.; Suzuki, R.; Kurono, M.; Takada, Y.; Shioya, H.; Komiya, T.; Mizuno, H.; Ono, T.; Hagiya, H.; Minami, M.; Nakade, S.; Habashita, H. Discovery of S1P agonists with a dihydronaphthalene scaffold Bioorg. Med. Chem. Lett. 2011, 21, 3885-3889
99. Kurata, H.; Kusumi, K.; Otsuki, K.; Suzuki, R.; Kurono, M.; Tokuda, N.; Takada, Y.; Shioya, H.; Mizuno, H.; Komiya, T.; Ono, T.; Hagiya, H.; Minami, M.; Nakade, S.; Habashita, H. Structure-activity relationship studies of S1P agonists with a dihydronaphthalene scaffold Bioorg. Med. Chem. Lett. 2012, 22, 144-148
100. Kurata, H.; Otsuki, K.; Kusumi, K.; Kurono, M.; Terakado, M.; Seko, T.; Mizuno, H.; Ono, T.; Hagiya, H.; Minami, M.; Nakade, S.; Habashita, H. Structure-activity relationship studies of sphingosine-1-phosphate receptor agonists with N -cinnamyl-beta-alanine moiety Bioorg. Med. Chem. Lett. 2011, 21, 1390-1393
101. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 (Pubitemid 34595232)
102. Sanada, Y.; Mizushima, T.; Kai, Y.; Nishimura, J.; Hagiya, H.; Kurata, H.; Mizuno, H.; Uejima, E.; Ito, T. Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis PLoS One 2011, 6, e23933
103. Kotelevets, N.; Fabbro, D.; Huwiler, A.; Zangemeister-Wittke, U. Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis PLoS One 2012, 7, e39209
104. Cragg, G. M.; Newman, D. J.; Snader, K. M. Natural products in drug discovery and development J. Nat. Prod. 1997, 60, 52-60 (Pubitemid 27052102)
105. Kuroda, I.; Musman, M.; Ohtani, I. I.; Ichiba, T.; Tanaka, J.; Gravalos, D. G.; Higa, T. Pachastrissamine, a cytotoxic anhydrophytosphingosine from a marine sponge, Pachastrissa sp J. Nat. Prod. 2002, 65, 1505-1506 (Pubitemid 35239644)
106. Ballereau, S.; Baltas, M.; Genisson, Y. Sphingolipids cyclic derivatives: occurrence, biological relevance and synthetic approaches Curr. Org. Chem. 2011, 15, 953-986
107. Yoshimitsu, Y.; Oishi, S.; Miyagaki, J.; Inuki, S.; Ohno, H.; Fujii, N. Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C Bioorg. Med. Chem. 2011, 19, 5402-5408
108. Ledroit, V.; Debitus, C.; Lavaud, C.; Massiot, G. Jaspines A and B: two new cytotoxic sphingosine derivatives from the marine sponge Jaspis sp Tetrahedron Lett. 2003, 44, 225-228 (Pubitemid 35449550)
109. Salma, Y.; Lafont, E.; Therville, N.; Carpentier, S.; Bonnafe, M. J.; Levade, T.; Genisson, Y.; Andrieu-Abadie, N. The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism Biochem. Pharmacol. 2009, 78, 477-485
110. Yoo, H.; Lee, Y. S.; Lee, S.; Kim, S.; Kim, T. Y. Pachastrissamine from Pachastrissa sp. inhibits melanoma cell growth by dual inhibition of Cdk2 and ERK-mediated FOXO3 downregulation Phytother. Res. 2012, 26, 1927-1933
111. Canals, D.; Mormeneo, D.; Fabrias, G.; Llebaria, A.; Casas, J.; Delgado, A. Synthesis and biological properties of pachastrissamine (jaspine B) and diastereoisomeric jaspines Bioorg. Med. Chem. 2009, 17, 235-241
112. Jeon, H.; Bae, H.; Baek, D. J.; Kwak, Y. S.; Kim, D.; Kim, S. Syntheses of sulfur and selenium analogues of pachastrissamine via double displacements of cyclic sulfate Org. Biomol. Chem. 2011, 9, 7237-7242
113. Salma, Y.; Ballereau, S.; Maaliki, C.; Ladeira, S.; Andrieu-Abadie, N.; Genisson, Y. Flexible and enantioselective access to jaspine B and biologically active chain-modified analogues thereof Org. Biomol. Chem. 2010, 8, 3227-3243
114. Rives, A.; Ladeira, S.; Levade, T.; Andrieu-Abadie, N.; Genisson, Y. Synthesis of cytotoxic aza analogues of jaspine B J. Org. Chem. 2010, 18, 18
115. Kono, K.; Tanaka, M.; Mizuno, T.; Kodama, K.; Ogita, T.; Kohama, T. B-535a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination J. Antibiot. 2000, 53, 753-758
116. Kono, K.; Tanaka, M.; Ogita, T.; Kohama, T. Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium J. Antibiot. 2000, 53, 759-764
117. Liu, H.; Sugiura, M.; Nava, V. E.; Edsall, L. C.; Kono, K.; Poulton, S.; Milstien, S.; Kohama, T.; Spiegel, S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform J. Biol. Chem. 2000, 275, 19513-19520 (Pubitemid 30441543)
118. Park, M. T.; Kang, J. A.; Choi, J. A.; Kang, C. M.; Kim, T. H.; Bae, S.; Kang, S.; Kim, S.; Choi, W. I.; Cho, C. K.; Chung, H. Y.; Lee, Y. S.; Lee, S. J. Phytosphingosine induces apoptotic cell death via caspase 8 activation and Bax translocation in human cancer cells Clin. Cancer Res. 2003, 9, 878-885 (Pubitemid 36182628)
119. Nagahara, Y.; Shinomiya, T.; Kuroda, S.; Kaneko, N.; Nishio, R.; Ikekita, M. Phytosphingosine induced mitochondria-involved apoptosis Cancer Sci. 2005, 96, 83-92 (Pubitemid 40425383)
120. Choi, S. Y.; Kim, M. J.; Chung, H. Y.; Lee, S. J.; Jang, Y. J. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5 Oncol. Rep. 2007, 17, 175-184
121. Park, M. T.; Kim, M. J.; Kang, Y. H.; Choi, S. Y.; Lee, J. H.; Choi, J. A.; Kang, C. M.; Cho, C. K.; Kang, S.; Bae, S.; Lee, Y. S.; Chung, H. Y.; Lee, S. J. Phytosphingosine in combination with ionizing radiation enhances apoptotic cell death in radiation-resistant cancer cells through ROS-dependent and -independent AIF release Blood 2005, 105, 1724-1733 (Pubitemid 40223696)
122. Kim, B. M.; Choi, Y. J.; Han, Y.; Yun, Y. S.; Hong, S. H. N, N -Dimethyl phytosphingosine induces caspase-8-dependent cytochrome c release and apoptosis through ROS generation in human leukemia cells Toxicol. Appl. Pharmacol. 2009, 239, 87-97
123. Park, S. R.; Cho, H. J.; Moon, K. J.; Chun, K. H.; Kong, S. Y.; Yoon, S. S.; Lee, J. S.; Park, S. Cytotoxic effects of novel phytosphingosine derivatives, including N, N -dimethylphytosphingosine and N - monomethylphytosphingosine, in human leukemia cell line HL60 Leuk. Lymphoma 2010, 51, 132-145
124. Moon, B. S.; Park, M. T.; Park, J. H.; Kim, S. W.; Lee, K. C.; An, G. I.; Yang, S. D.; Chi, D. Y.; Cheon, G. J.; Lee, S. J. Synthesis of novel phytosphingosine derivatives and their preliminary biological evaluation for enhancing radiation therapy Bioorg. Med. Chem. Lett. 2007, 17, 6643-6646 (Pubitemid 350030883)
125. Kono, K.; Tanaka, M.; Ogita, T.; Hosoya, T.; Kohama, T. F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete J. Antibiot. 2000, 53, 459-466 (Pubitemid 30345262)
126. Maezawa, N.; Furuichi, N.; Tsuchikawa, H.; Katsumura, S. Synthesis of a novel sphingosine kinase inhibitor (-)-F-12509A and determination of its absolute configuration Tetrahedron Lett. 2007, 48, 4865-4867 (Pubitemid 46891539)
127. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1 Leukemia 2006, 20, 95-102
128. Bonhoure, E.; Lauret, A.; Barnes, D. J.; Martin, C.; Malavaud, B.; Kohama, T.; Melo, J. V.; Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells Leukemia 2008, 22, 971-979 (Pubitemid 351689879)
129. Brizuela, L.; Dayon, A.; Doumerc, N.; Ader, I.; Golzio, M.; Izard, J. C.; Hara, Y.; Malavaud, B.; Cuvillier, O. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer FASEB J. 2010, 24, 3882-3894
130. Zu Heringdorf, D. M.; Ihlefeld, K.; Pfeilschifter, J. Pharmacology of the sphingosine-1-phosphate signalling system Handb. Exp. Pharmacol. 2013, 215, 239-253
131. Edmonds, Y.; Milstien, S.; Spiegel, S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling Pharmacol. Ther. 2011, 132, 352-360
132. Song, J.; Hagiya, H.; Kurata, H.; Mizuno, H.; Ito, T. Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation Transpl. Immunol. 2012, 26, 163-170
133. Lauer, S. A.; Ghori, N.; Haldar, K. Sphingolipid synthesis as a target for chemotherapy against malaria parasites Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 9181-9185
134. Meyer, E. V. S.; Holt, J. J.; Girard, K. R.; Ballie, M. T.; Bushnev, A. S.; Lapp, S.; Menaldino, D. S.; Arrendale, R. F.; Reddy, G. P.; Evers, T. J.; Howard, R. B.; Culver, D. G.; Liotta, D. C.; Galinski, M. R.; Natchus, M. G. Sphingolipid analogues inhibit development of malaria parasites ACS Med. Chem. Lett. 2011, 3, 43-47
135. Alexander, S.; Swatson, W. S.; Alexander, H. Pharmacogenetics of resistance to cisplatin and other anticancer drugs and the role of sphingolipid metabolism Methods Mol. Biol. 2013, 983, 185-204
136. Salas, A.; Ponnusamy, S.; Senkal, C. E.; Meyers-Needham, M.; Selvam, S. P.; Saddoughi, S. A.; Apohan, E.; Sentelle, R. D.; Smith, C.; Gault, C. R.; Obeid, L. M.; El-Shewy, H. M.; Oaks, J.; Santhanam, R.; Marcucci, G.; Baran, Y.; Mahajan, S.; Fernandes, D.; Stuart, R.; Perrotti, D.; Ogretmen, B. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A Blood 2011, 117, 5941-5952
137. Schnitzer, S. E.; Weigert, A.; Zhou, J.; Brune, B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells Mol. Cancer Res. 2009, 7, 393-401
138. Gustin, D. J.; Li, Y.; Brown, M. L.; Min, X.; Schmitt, M. J.; Wanska, M.; Wang, X.; Connors, R.; Johnstone, S.; Cardozo, M.; Cheng, A. C.; Jeffries, S.; Franks, B.; Li, S.; Shen, S.; Wong, M.; Wesche, H.; Xu, G.; Carlson, T. J.; Plant, M.; Morgenstern, K.; Rex, K.; Schmitt, J.; Coxon, A.; Walker, N.; Kayser, F.; Wang, Z. Structure guided design of a series of sphingosine kinase (SphK) inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 4608-4616
139. Neubauer, H. A.; Pitson, S. M. Roles, regulation and inhibitors of sphingosine kinase 2 FEBS J. 2013, 280, 5317-5336
140. Urbano, M.; Guerrero, M.; Rosen, H.; Roberts, E. Modulators of the sphingosine 1-phosphate receptor 1 Bioorg. Med. Chem. Lett. 2013, 23, 6377-6389
141. Rex, K.; Jeffries, S.; Brown, M. L.; Carlson, T.; Coxon, A.; Fajardo, F.; Frank, B.; Gustin, D.; Kamb, A.; Kassner, P. D.; Li, S.; Li, Y.; Morgenstern, K.; Plant, M.; Quon, K.; Ruefli-Brasse, A.; Schmidt, J.; Swearingen, E.; Walker, N.; Wang, Z.; Watson, J. E. V.; Wickramasinghe, D.; Wong, M.; Xu, G.; Wesche, H. Sphingosine kinase activity is not required for tumor cell viability PLoS One 2013, 8, e68328
142. Beljanski, V.; Lewis, C. S.; Smith, C. D. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts Cancer Biol. Ther. 2011, 11, 524-534
143. Li, Q. F.; Yan, J.; Zhang, K.; Yang, Y. F.; Xiao, F. J.; Wu, C. T.; Wang, H.; Wang, L. S. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1 Biochem. Biophys. Res. Commun. 2011, 405, 31-36
144. Chatzakos, V.; Rundlof, A. K.; Ahmed, D.; de Verdier, P. J.; Flygare, J. Inhibition of sphingosine kinase 1 enhances cytotoxicity, ceramide levels and ROS formation in liver cancer cells treated with selenite Biochem. Pharmacol. 2012, 84, 712-721